Next Generation News and Research

RSS

UCLA's Laboratory of Neuro Imaging awarded $1.9 million NIH ARRA grant

UCLA researchers have received 80 American Recovery and Reinvestment Act of 2009 (Recovery Act) grants totaling $19.4 million from the National Institutes of Health thus far. UCLA's largest NIH ARRA grant to date was $1.9 million, awarded to UCLA's Laboratory of Neuro Imaging (LONI), which is dedicated to creating scientific approaches to mapping how the brain is structured and how it works.

24 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Coherex Medical raises $16.5 million from venture capital firms

Coherex Medical, Inc. today announced that it has closed a $16.5 million Series B Preferred Stock financing. After the close of this investment, Coherex has now raised nearly $28.0 million in equity financing from outside funding sources since inception.

21 Aug 2009

AMDL Diagnostics to focus on in vitro diagnostic cancer tests

AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced the inauguration of AMDL Diagnostics Inc. (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure(TM)-- AMDL's proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

21 Aug 2009

Bayer Crop Science uses Chromatin's proprietary mini-chromosome technology

Chromatin Inc. and Bayer CropScience announced today that they have entered into a technological alliance and license agreement to use Chromatin’s proprietary mini-chromosome technology for crop improvement.

20 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

Patterson Companies records 6% year-on-year sales growth in first-quarter

Patterson Companies, Inc. today reported consolidated sales of $789,579,000 for the first quarter of fiscal 2010 ended July 25, an increase of 6% from $743,859,000 in the year-earlier quarter. The strong performance of technology offerings in the dental equipment business, as well as higher sales of veterinary supplies, helped offset the impact of the weak economy on other portions of Patterson’s business. Acquisitions, net of negative foreign currency adjustments, accounted for the majority of the first quarter sales growth. Net income was $45,057,000 or $0.38 per diluted share, compared to $45,964,000 or $0.39 per diluted share in the first quarter of 2009.

20 Aug 2009

3M introduces Littmann electronic stethoscope with Bluetooth

Taking the stethoscope into the 21st century, 3M today announced the introduction of the 3M™ Littmann® Electronic Stethoscope Model 3200, a next-generation auscultation device featuring Bluetooth technology that wirelessly transfers heart, lung and other body sounds to software for further analysis.

19 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

Kolltan Pharmaceuticals raises additional $5 million to close Series A financing

Kolltan Pharmaceuticals, Inc. announced today that it has raised an additional $5 million to close its Series A preferred stock financing at $40 million. Participants in the Series A financing, originally announced in January 2009, include Purdue Pharma, L.P., HBM BioCapital L.P., the Pritzker/Vlock family, and other substantial private life science investors.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Weight training reduces lymphedema symptoms after breast cancer surgery

Breast cancer survivors who lift weights are less likely than their non-weightlifting peers to experience worsening symptoms of lymphedema, the arm- and hand-swelling condition that plagues many women following surgery for their disease, according to new University of Pennsylvania School of Medicine research published in the August 13 issue of the New England Journal of Medicine.

18 Aug 2009

Remarkable vision improvements after gene therapy for inherited blindness

One year after a trio of young adults received gene therapy for an inherited form of blindness, researchers have documented that the patients are still experiencing the same level of remarkable vision improvements previously measured within weeks.

13 Aug 2009

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) announced today they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

12 Aug 2009

New personal assistance voice dialer for seniors who need to call for help in an emergency

eMed-ID, the world's first emergency medical device franchise, announced today the launch of eMed-Alert, a next-generation personal assistance voice dialer designed for seniors who may need to call for help in an emergency. With more than 11 million Americans age 65 and older living alone today, eMed-Alert provides seniors a way to maintain their independence.

11 Aug 2009

Febit's DNA-capture method selected by NCGR to re-sequence 400 genes involved in childhood diseases

The National Center for Genome Resources (NCGR) has selected febit's DNA-capture method, HybSelect, to re-sequence the exons of genes involved in over 400 of the most devastating childhood diseases with the ultimate goal of developing genetic tests to detect carrier status for recessive genetic diseases in prospective parents.

11 Aug 2009

New class of molecules capable of blocking formation of tau protein fibrils

A new class of molecules capable of blocking the formation of specific protein clumps that are believed to contribute to Alzheimer’s disease pathology has been discovered by researchers at the University of Pennsylvania School of Medicine. By assaying close to 300,000 compounds, they have identified drug-like inhibitors of AD tau protein clumping, as reported in the journal Biochemistry.

11 Aug 2009

GE Global Research Biosciences technology celebrated fifth anniversary

From creating a new business in digital pathology to developing next generation diagnostic imaging agents and life sciences tools that are breaking new ground in the detection and treatment of disease, the Biosciences technology organization at GE Global Research today celebrated its fifth anniversary.

6 Aug 2009

Protein unfolding key to understanding blood clot mechanics

Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers -- a blood clot -- that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?

6 Aug 2009

A new startup at California Nanosystems Institute

UCLA's newly launched on-campus technology incubator at the California NanoSystems Institute (CNSI) has opened lab space to MediSens Wireless, a startup company that develops and manufactures personal body-monitoring systems for medical and health applications.

6 Aug 2009